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Abstract
Background: Altered expression of DNA polymerase b (Pol b) has been documented in a large percentage of human
tumors. However, tumor prevalence or predisposition resulting from Pol b over-expression has not yet been evaluated in a
mouse model.
Methodology/Principal Findings: We have recently developed a novel transgenic mouse model that over-expresses Pol b.
These mice present with an elevated incidence of spontaneous histologic lesions, including cataracts, hyperplasia of
Brunner’s gland and mucosal hyperplasia in the duodenum. In addition, osteogenic tumors in mice tails, such as osteoma
and osteosarcoma were detected. This is the first report of elevated tumor incidence in a mouse model of Pol b over-
expression. These findings prompted an evaluation of human gastrointestinal tumors with regard to Pol b expression. We
observed elevated expression of Pol b in stomach adenomas and thyroid follicular carcinomas, but reduced Pol b expression
in esophageal adenocarcinomas and squamous carcinomas.
Conclusions/Significance: These data support the hypothesis that balanced and proficient base excision repair protein
expression and base excision repair capacity is required for genome stability and protection from hyperplasia and tumor
formation.
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Introduction
Increasing evidence is emerging that a large percentage of
human tumors have elevated expression of DNA polymerase b
(Pol b) [1] and in many cases, mutations within the Pol b coding
region results in over-expression of dysfunctional Pol b proteins
[2]. High levels of Pol b expression have been demonstrated in
several human cancers and tumor cell lines [3–6]. Specifically,
elevated Pol b expression is observed in esophageal cancer [7],
colorectal cancer [8] and pancreatic cancer [9]. Ectopic Pol b
expression in human cancer cells is associated with aneuploidy,
abnormal localization of centrosome-associated gamma tubulin
protein expression during mitosis, increased microsatellite insta-
bility [8,10] and is found to promote tumorigenesis in immuno-
deficient nude mice [4,5]. Recently, infection by several viruses
associated with elevated cancer incidence, including chronic
myelogenous leukemia (CML) [11], human papillomavirus 16
(HPV16) [12] and Epstein-Barr virus (EBV) [13], has been shown
to induce the expression of Pol b to elevated levels. Furthermore,
approximately 30% of human cancers express mutant or aberrant
forms of Pol b proteins [2,14–16], leading to genomic instability
and possibly conferring a mutator phenotype to cells [3,17,18].
Taken together, current evidence indicates an imbalance in Pol b
expression, either increased or decreased, leads to functional
deficiency of the base excision repair pathway and promotes
genomic instability [3,17,18].
As a key enzyme in the base excision repair (BER) pathway, Pol
b is essential for the efficient repair of DNA lesions damaged by
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endogenous and exogenous genotoxins [19]. Once the base lesion
is removed and the DNA backbone is hydrolyzed by the concerted
action of a lesion-specific DNA glycosylase such as Methyladenine
DNA Glycosylase (MPG) and Apurinic/apyrimidinic endonucle-
ase 1 (APE1), the resulting single-nucleotide gap is ‘tailored’ by the
59dRP lyase activity of Pol b and subsequently, Pol b adds a
nucleotide to fill the gap. Repair is then completed by the
XRCC1/LigIIIa heterodimer [20]. BER is severely attenuated in
the absence of Pol b, leading to an increase in cellular sensitivity to
several genotoxins [21–26], increased spontaneous and damage-
induced mutations and genome rearrangements in knockout (KO)
or knockdown (KD) cells [17,27,28] and KO (+/2) mice [29].
However, complete KO (2/2) is lethal in mice just after birth
[30,31] preventing detailed analysis of Pol b deficiency beyond
embryo development where it is found that Pol b KO neurons die
by p53-dependent apoptosis [32] resulting in an increase in
mutation frequency in the remaining embryonic tissue [33].
Pol b is involved in many essential protein-protein interactions
among the various BER proteins [20], yet some Pol b binding
proteins suggest additional functions outside of BER, as evidenced
by an interaction with the telomere protein TRF2 [34], the ATM
binding protein ATMIN (ASCIZ) [35,36], the 9-1-1 checkpoint
complex [37], the histone acetyltransferase MYST2 [38] or the
transcription factor TAF1D (JOSD3, MGC5306) [39]. The
functional significance of many of these potential interactions has
yet to be revealed. However, Pol b was identified by ChIP analysis
as a component of the telomere protein complex [40], a role that is
likely related to its interaction with TRF2 [34]. These significant
protein-protein interactions and the role of Pol b in BER or other
DNA metabolic functions can clearly be impacted by protein
expression changes that would disrupt complex formation.
In addition to control via transcription or translation, Pol b is
also regulated post-translationally via acetylation [41], methylation
[42,43] and ubiquitylation [44,45]. These varied modes of Pol b
regulation can impact not only Pol b function directly, but changes
in expression or in specific post-translational modifications (PTM)
can alter function (loss of stability or loss of function due to PTM)
or can impact complex formation (loss of protein-protein
interactions due to PTM) [20] and lead to repair defects even
when Pol b is expressed at high levels.
Transgenic mice with over-expression of the Flag-Pol b
transgene were developed here to study the consequences of this
effect on imbalanced base excision repair and carcinogenesis. As
part of the characterization of this animal model, we report the
age-associated histopathological changes present in two-year old
Pol b transgenic mice. We find that mice over-expressing Pol b
develop Brunner’s gland hyperplasia, mucosal hyperplasia in the
duodenum and osteogenic tumors in the tail. This was the impetus
for an analysis of Pol b expression in relevant human
gastrointestinal tumors and the surrounding normal tissue.
Paradoxically, we find that whereas stomach adenocarcinoma
and thyroid follicular carcinoma present with slightly elevated
expression of Pol b, both esophageal squamous carcinoma and
esophageal adenocarcinoma show a significant decrease in Pol b
expression, compared with surrounding pathologically normal
tissue. Overall, these studies support the hypothesis that balanced
and proficient BER protein expression and BER capacity is
required for genome stability and protection from hyperplasia and
tumor formation.
Results
It is our hypothesis that altered expression of Pol b and the
resulting imbalance in BER can predispose to tumor formation.
To test this hypothesis, we analyzed transgenic mice that present
with elevated expression of Pol b [46]. These Pol b transgenic (Tg)
mice express Flag-tagged Pol b (TetOp-Flag-Polb-tTA) and were
described previously [46]. In this present study, the Tg mice were
crossed .5 generations to the C57Bl/6 strain. In rare cases,
Figure 1. Expression of Flag-Pol b in MEFs and tissues from Pol
b Tg mice. (A) Specificity of mouse and human qRT-PCR analysis for Pol
b expression: RNA was isolated from WT and Pol b KO MEFs and MEFs
expressing the Flag-Pol b transgene, as described in the Methods
section. The relative level of expression of both the mouse (open bars)
and human (filled bars) Pol b mRNA (normalized to mouse b-actin) was
determined using mouse and human specific Taqman assays.
Expression across samples was normalized to the expression level in
the WT/Flag-Pol b MEF sample. (B) Expression of the human Pol b
transgene in mouse tissues and tumors: RNA was isolated from the
sample indicated in the plot, as described in the Methods section. The
relative level of expression of human Pol b mRNA (open bars;
normalized to mouse b-actin) was determined using human specific
Taqman assays as in panel A. Expression across samples was normalized
to the expression level in the Tg Brain sample.
doi:10.1371/journal.pone.0006493.g001
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repression of transgene expression has been reported, depending
on the transgene, the promoter used for expression and its location
[47–49]. To verify that expression of the Flag-Pol b transgene was
maintained and was not epigenetically silenced during the
backcrosses from the original Tg strain to C57BL/6 mice,
expression was verified by qRT-PCR of RNA purified from tissue
isolated by laser-capture microdissection. The Pol b human
transgene used herein has 90.8% sequence identity to the mouse
Pol b cDNA (not shown) so we first verified that the Taqman gene
expression assays were specific for each mRNA. RNA was isolated
from wild-type (WT) mouse embryonic fibroblasts (MEFs), Pol b
KO MEFs and WT MEFs that express the Flag-Pol b transgene
used in this study. The relative level of expression of either the
mouse or human Pol b mRNA was determined for each sample
and normalized to the expression of mouse b-actin using the
DDCT protocol, as described in the Methods section. As shown in
Figure 1A, the expression of both mouse and human Pol b was
normalized to the expression level in the transgenic cell line WT/
Flag-Pol b. A similar level of expression of mouse Pol b was
observed in the WT MEF cell line but no expression of mouse Pol
b was detected in the Pol b KO cell line, as expected [21,22].
Similarly, the expression of the human Pol b transgene was only
detected in the WT/Flag-Pol b MEF cells (filled bar, Figure 1A)
with no detectable expression in either the WT MEF cells or the
Pol b KO MEF cells. This analysis demonstrates the specificity of
both the mouse and human Taqman gene expression assays. It
should be noted that we used this approach to validate the
specificity of a second Taqman gene expression assay for human
Pol b (Hs00160263_m1). However, this assay cross-reacted with
the mouse mRNA and was not used.
Using the validated gene expression assays and the DDCT protocol
as described above and in the Methods section, we next determined if
the human Flag-Pol b transgene was expressed in the cells of the tissues
of interest and most importantly, in the tumors. Using laser-capture
microdissection, we isolated and purified RNA from the brain (not
shown) and the normal and tumor samples described in Figure 2, as
well as from cells from a non-transgenic (non-Tg) mouse. Previous
studies (not shown) suggested that the expression of the Flag-Pol b
transgene in the brain was low but detectable [46] and so the relative
quantitation of Flag-Pol b expression was normalized to the level of
expression in the brain (Figure 1B). As shown, the level of expression in
normal duodenum tissue was slightly elevated as compared to the
Figure 2. Representative photomicrographs (H & E stain) of duodenal changes in Pol b Tg mice. (A) Normal duodenum. Note normal
Brunner’s glands (arrows) (magnification620). (B) Diffuse hyperplasia of Brunner’s glands (small arrows) and duodenal crypt epithelium (large arrow).
Note markedly increased mucosal thickness due to glandular hyperplasia, compared to panel A (magnification620). (C) Cystic dilatation of mucosal
crypts and Brunner’s glands with displacement of cystic glands into the tunica muscularis (magnification6200). (D) Focal proliferation of dysplastic
glands in a mouse diagnosed with duodenal adenoma (magnification6400).
doi:10.1371/journal.pone.0006493.g002
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brain, similar to that observed in our previous analysis of this Tgmouse
[46]. However, expression in the hyperplastic duodenum was
approximately 7-fold higher than the brain and 2- to 3-fold higher
than the normal duodenum tissue. These studies therefore confirm that
the Flag-Pol b transgene is expressed at elevated levels depending on
the tissue andmost importantly, the transgene expression appears to be
further elevated in the tumors (Figure 1B). Further, these results suggest
that the expression of the Flag-Pol b transgene is elevated in these mice
similar to that reported earlier [46].
We therefore evaluated the spectrum of pathological lesions in a
cohort of our Pol b Tg mice at 2 years of age. Macroscopic lesions
are summarized in Table 1 and non-neoplastic and neoplastic
lesions are summarized in Tables 2 through 4. Morphological
characteristics of some of the main lesions are as follows in the
sections below.
Proliferative lesions of the duodenum
Hyperplasia of Brunner’s glands and hyperplasia of the
duodenal crypt epithelium resulting in markedly thickened
duodenal mucosa was detected in four of 15 male mice (26.7%)
and ten of 21 female mice (47.6%) (compare Figure 2A and 2B).
Proliferative lesions, especially around Vater’s papilla, were
Table 1. Incidence of macroscopic findings observed in DNA
polymerase b Tg mice.
Organ Macroscopic Finding Frequency (%)*
Male
(n =15)
Female
(n=21)
Abdominal cavity Fluid 13.3 19.0
Mass/Nodule 6.7 0.0
Heart Enlarged 13.3 0.0
Soft 0.0 4.8
Salivary gland Atrophy 0.0 28.6
Mass/Nodule 0.0 9.5
Liver Cysts 6.7 28.6
Enlarged 0.0 9.5
Mottled 20.0 9.5
Mass/Nodule 20.0 9.5
Duodenum Thickened, red 0.0 14.3
Mass/Nodule 13.3 23.8
Jejunum Mass 6.7 4.8
Ileum Mass 0.0 4.8
Colon Mass 6.7 0.0
Adrenal Enlarged 6.7 4.8
Pituitary gland Dark, cystic 0.0 4.8
Spleen Enlarged 6.7 38.0
White Foci 6.7 0.0
Small/Atrophy 6.7 4.8
Mass/Nodule 6.7 4.8
Thymus Enlarged 0.0 4.8
Mesenteric Lymph Node Enlarged 40.0 48
Mass/Nodule 0.0 4.8
Other Lymph Node Enlarged 20.0 38.1
Testis Dark red 6.7 –
Seminal vesicle Black, cystic 6.7 –
Enlarged 20.0 –
Prostate Enlarged 6.7 –
Ovary Dark red – 19.0
Uterus Dilated – 4.8
Lung Pale 6.7 0.0
Ear Ulcer 0.0 4.8
Eye Lens, white 100 100
Tail Mass/Nodule 33.3 14.3
*Frequency defined as the number of animals with the lesion divided by the
number of animals with the tissue examined macroscopically, multiplied by
100.
doi:10.1371/journal.pone.0006493.t001
Table 2. Incidence of non-neoplastic lesions observed in DNA
polymerase b Tg mice.
Organ Macroscopic Finding Frequency (%)*
Male
(n =15)
Female
(n=21)
Heart Polyarteritis 6.7 0.0
Salivary gland Mononuclear cell, infiltration 93.3 45.0
Duodenum Erosion 0.0 9.5
Ectopic pancreas 0.0 4.8
Liver Altered cell foci 6.7 4.8
Biliary cyst 6.7 14.3
Chronic active hepatitis 13.3 0.0
Erythrophagocytosis 0.0 4.8
Extramedullary hematopoiesis 6.7 14.3
Hemorrhage 20.0 4.8
Hyaline bodies, cytoplasm 6.7 0.0
Microgranulation 0.0 4.8
Mononuclear cell, infiltration 53.3 47.6
Necrosis 13.3 14.3
Pigmentation 0.0 4.8
Subcapsular infiltration 0.0 4.8
Gallbladder Hyaline inclusion 27.3 5.0
Pancreas Mononuclear cell, infiltration 0.0 19.0
Adrenal gland Pigmentation 33.3 95.2
Mesenteric Lymph Node Erythrophagocytosis 0.0 8.3
Other Lymph Node Plasmacytosis 6.7 0.0
Spleen Congestion 0.0 4.8
Extramedullary hematopoiesis 73.3 75.0
Mammary gland Lactation – 5.6
Testis Sperm granuloma 14.3 –
Hemorrhage 7.1 –
Tubular, atrophy 7.1 –
Epididymis Hypospermia 7.7 –
Prostate Mononuclear cell, infiltration 6.7
Polyarteritis 6.7
Seminal vesicle Hemorrhage 6.7
*Frequency defined as the number of animals with the lesion divided by the
number of animals with the tissue examined histopathologically, multiplied by
100. Abnormal non-neoplastic changes were not detected in thyroid,
parathyroid, thymus, stomach, jejunum, ileum, cecum, colon and pituitary.
doi:10.1371/journal.pone.0006493.t002
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detected with high incidence. Such changes were characterized by
diffuse epithelial hyperplasia, altered epithelial differentiation,
eosinophilic cytoplasmic inclusions, and herniation/diverticulation
(Figure 2C) of the epithelium into the tunica muscularis and
serosa. Adenoma of relatively small size, was diagnosed in one of
21 female mice (Figure 2D). Proliferative lesions were often
associated with chronic granulomatous inflammation and are
similar to duodenal plaques (avillous hyperplasia, duodenum
polyp) derived from the crypts of Lieberkuhn [50]. Most of these
lesions are regarded as benign hyperplastic lesions, but some may
develop dysplasia, a pre-malignant neoplastic lesion.
Osteogenic tumors in tail
Macroscopically, masses or nodules in the tail were detected in
33.3% (5/15) of male and 14.3% (3/21) of female mice.
Histopathologically, chondro-osseous metaplasia was detected in
one of 3 female mice; osteoma was detected in three of 5 male mice
(Figure 3A and 3B); and osteosarcoma was detected in one of 5 male
and one of 3 female mice (Figure 3C and 3D). Osteosarcoma was
characterized by proliferating spindle tumor cells, associated with
presence of irregular, infiltrating trabecular bone. In this study,
osteogenic tumors were not detected in any other site besides the tail.
Mature Cataract
Mature cataracts were detected in all mice examined (male; 13/
13, female; 21/21), essentially as we described previously [46].
Histopathologically, the lens changes were characterized by
degeneration/necrosis (liquefaction), vacuole formation in most
of the lens fibers, and irregular proliferation of lens fiber spindle
cells, followed by calcification (Figure 4A and 4B). Moreover, lens
epithelia with bizarre nuclei and single cell necrosis in the
proliferative fiber cells were seen. In all cases, lenticular lesions
were diagnosed as a mature type, a final stage of cataract
formation.
Renal lesions
A spectrum of renal lesions was detected in almost all animals
with glomerular changes, basophilic tubules, and mononuclear cell
infiltration occurring in both sexes. Glomerular hyalinization was
detected in almost all mice (male; 15/15, female; 17/20) with
basement membrane thickening (Figure 4C and 4D). In mild
cases, eosinophilic material in glomerular basement membranes
was seen, while densely eosinophilic and amorphous deposits in
glomeruli were seen in severe cases. In addition, glomerular
hypercellularity, consistent with proliferation of mesangial cells,
was present in 3 of 15 male and 4 of 20 female mice. Moreover,
basophilic tubules observed in the cortex of 13 of 15 male and 16
of 20 female mice. These lesions are representative of glomeru-
lonephritis.
Expression of Pol b in human tumors and surrounding
normal tissue
To extend observations in mice, we examined Pol b expression
in human gastrointestinal cancers and in surrounding normal
epithelial tissues (Figure 5A). Because cancers are more likely to
arise in epithelial tissues, we separated scores in epithelial and
stromal (subepithelial) areas. There was no significant difference in
Pol b immunoreactivity scores between stromal areas in cancerous
vs. surrounding non-cancerous tissues. In epithelial tissues, we
observed (Figure 5B) elevated expression of Pol b in stomach
adenocarcinomas compared with surrounding normal gastric
mucosal tissue, although this difference was not significant
(p = 0.19). Compared with paired normal surrounding tissues,
however, there was a significant increase in Pol b in thyroid
follicular carcinomas (p = 0.02), but significantly reduced Pol b
expression in esophageal adenocarcinomas (p= 0.04) and squa-
mous carcinomas (p= 0.005).
Discussion
BER proteins require a finely tuned balance of expression to
ensure complete repair of many mutagenic or genome destabiliz-
ing base lesions [24,46,51–54]. Altered expression or mutations in
BER proteins such as Pol b that impact function or protein-protein
interactions can predispose to sensitivity to genotoxins [22], an
increase in genome alterations [17], mutations [27] and tumor
formation [55]. In total, cellular, epidemiological and pathological
analyses suggested a correlation between several human cancers
and Pol b mutations and/or expression changes.
In cell-based studies, alteration in expression of Pol b impacts
BER capacity and manifests as a genome destabilizing phenotype,
consistent with the observation that greater than 30% of human
tumors have elevated expression of Pol b [1] and in a separate
study it was revealed that greater than 30% of human tumors
express mutant forms of Pol b [2]. Only a few animal models with
altered Pol b expression have been characterized to study how
alterations in Pol b expression might impact tumor formation in
Table 3. Incidence of non-neoplastic lesions observed in DNA
polymerase b Tg mice.
Organ Macroscopic Finding Frequency (%)*
Male
(n =15)
Female
(n =21)
Ovary Atrophy – 94.4
Cyst – 60.0
Thrombus – 5.6
Vagina Erosion – 50.0
Lung Mononuclear cell, infiltration 60.0 57.1
Eye Cataract 100.0 100.0
Kidney Basophilic tubules 86.7 80.0
Glomerular, hyalinization 100.0 85.0
Glomerular, hypercellularity 20.0 20.0
Mononuclear cell, infiltration 80.0 85.0
Tubular, vacuolization 93.3 0.0
Hyaline droplet 0.0 15.0
Protein cast 0.0 10.0
Pelvic, dilatation 0.0 5.0
Skin Ulcer 0.0 5.0
Crust 0.0 5.0
Mononuclear cell, infiltration 0.0 10.0
Brain Mineralization 53.3 15.8
Hemosiderin deposition 6.7 0.0
Lateral ventricle, dilatation 13.3 0.0
Mononuclear cell, infiltration 0.0 5.3
Polyarteritis 6.7 0.0
Urinary bladder Mononuclear cell, infiltration 8.3 38.1
Tail Chondro-osseous metaplasia – 33.3
*Frequency defined as the number of animals with the lesion divided by the
number of animals with the tissue examined histopathologically, multiplied by
100. Abnormal non-neoplastic changes were not detected in thyroid, parathyroid,
thymus, stomach, jejunum, ileum, cecum, colon and pituitary.
doi:10.1371/journal.pone.0006493.t003
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the whole animal. Mice with a partial deficiency in Pol b
expression (Pol b heterozygote mice) have an elevated mutant
frequency in male germ cells [27] and a small increase in the
incidence of lymphoid hyperplasia and adenocarcinoma [56].
Mice expressing a truncated form of Pol b (polbetaD) in mammary
glands showed an elevated incidence of tumor formation [55].
This mutant of Pol b is a splice-variant missing amino acids 208–
236 [57] however, this variant is not cancer specific [58]. A second
Pol b Tg mouse was developed but this model only expresses Pol b
in the thymus and elevated tumor formation was not observed
[59].
The development of the Pol b transgenic mice used in this study
and the Pol b expression pattern was described previously [46].
The Pol b Tg mice were backcrossed onto a C57BL background, a
strain widely used for development of transgenic mice and gene-
targeting experiments [60]. The majority of non-neoplastic and
neoplastic lesions observed in the Pol b Tg mice were considered
spontaneous and age-related as previously reported in C57BL and
other mouse strains [50,60–63]. The more commonly occurring
spontaneous lesions in C57BL/6 (e.g., lymphoma and histiocytic
sarcoma) were not increased in the Pol b Tg mice. Lesions unique
to the Pol b Tg mice were found in the duodenum, tail, eye, and
kidney. The increased incidence (100%) of lesions in the eye
(cataract) was described earlier [46].
The 39% incidence of proliferative duodenal lesions in the Pol b
Tg mice is considerably higher than previously reported incidences
of 4% [63] and 21% [64] in aged C57BL mice. Other
spontaneous plaquelike lesions or polyposis in the pyloric area of
the glandular stomach have been observed in C57BL/Ncr6129/
SvTer (B6,129) mice, 129/SvTer mice, Ahr-null mice, TGF b-1
heterozygous mice, Smad4 heterozygous mice, CYP1A2-null
mice, and B6C3F1 mice [65–70]. Moreover, C57BL mice have
been reported to be very susceptible to duodenal neoplasia
following some carcinogen treatments [71]. A majority of the non-
neoplastic lesions are considered spontaneous age-related and
have been reported in C57BL/6 and other mouse strains. The
incidence of the non-neoplastic lesions was not increased in the
DNA Polymerase b over-expressing Tg mice. In particular,
mononuclear cell infiltration in all of the organs (mainly
lymphocytes), ovarian cystic lesions and atrophy, and liver lesions
are very common lesions in aged C57BL/6 mice. As well, there
was no gender differences. Therefore, Pol b Tg mice might also be
suitable models for duodenal carcinogenicity following treatment
with appropriate carcinogens.
Duodenal epithelial tumors that develop from the intestinal type
or the pancreaticobiliary type mucosa of Vater’s papilla [72,73]
are relatively rare tumors in humans; the incidence rate of
adenoma is 0.04–0.62% and that of carcinoma is 0.2% in
postmortem or autopsy studies [74]. Molecular alterations in these
duodenal lesions are similar to those of colorectal tumors and
include K-ras mutation and the overexpression of p53, p21/Waf1,
p16, and/or APC [72,73,75]. Mice which carry a mutation in the
Apc gene have multiple neoplastic lesions in duodenum (42%),
jejunum (38%), stomach (25%), ileum (15%), and colon (8%) [76].
It is not known if altered expression of the above-mentioned genes
might be related to the pathogenesis of duodenal lesions in Pol b
Tg mice. Recently, it was reported that APC directly inhibits BER
[77]. It is therefore possible that APC functions to regulate BER,
Table 4. Incidence of non-neoplastic & neoplastic proliferative lesions in DNA polymerase b Tg mice.
Organ Lesion Frequency (%)* Organ Lesion Frequency (%)*
Male Female Male Female
Salivary gland Lymphoid hyperplasia 0.0 10.0 Other Lymph Node Lymphoid hyperplasia 5.6 3.8
Malignant lymphoma 0.0 15.0 Malignant lymphoma 11.1 15.4
Forestomach Squamous hyperplasia 0.0 5.0 Histiocytic sarcoma 0.0 30.8
Duodenum Bruner’s gland/Mucosa
Hyperplasia,
26.7 47.6 Spleen Lymphoid hyperplasia 13.3 25.0
Malignant lymphoma 6.7 5.0
Histiocytic sarcoma 6.7 5.0
Adenoma 0.0 4.8 Thymus Malignant lymphoma 0.0 50.0
Malignant lymphoma 6.7 4.8 Skin Lymphoid hyperplasia 6.7 5.0
Jejunum Malignant lymphoma 6.7 10.0 Squamous, hyperplasia 0.0 5.0
Liver Adenoma 13.3 0.0 Ovary Malignant lymphoma – 5.6
Histiocytic sarcoma 13.3 14.3 Histiocytic sarcoma – 5.6
Adrenal gland Cortical hyperplasia 16.7 9.5 Uterus Endometrial, hyperplasia – 31.6
Cortical spindle cell hyperplasia 0.0 90.5 Lung Lymphoid hyperplasia 6.7 9.5
Thyroid Follicular cell, hyperplasia 0.0 18.8 Malignant lymphoma 0.0 9.5
Follicular cell adenoma 0.0 6.3 Histiocytic sarcoma 6.7 4.8
Pituitary gland Hyperplasia 0.0 25.0 Bronchiolar-alveolar
adenoma
20.0 0.0
Mesenteric Lymph Node Lymphoid hyperplasia 9.0 0.0 Kidney Malignant lymphoma 0.0 5.0
Malignant lymphoma 63.6 58.3 Tail Osteoma 60.0 0.0
Histiocytic sarcoma 9.0 25.0 Osteosarcoma 20.0 33.3
*Frequency defined as the number of animals with the lesion divided by the number of animals with the tissue examined histopathologically, multiplied by 100. Data
derived from 15 males and 21 females except where noted. No neoplastic changes were detected in gallbladder, parathyroid, thymus, ileum, cecum, colon, pancreas,
brain, eye, urinary bladder, testis, epididymis, prostate, seminal vesicle, oviduct, vagina, and mammary gland.
doi:10.1371/journal.pone.0006493.t004
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suggesting that Pol b over-expression may lead to a similar
phenotype as APC deficiency.
Spontaneous occurrence of osteogenic tumors is extremely rare in
rats and mice, and there are only a few reports published with
incidences of 0.1 to 2% in mice and 0 to 4% in rats [50,78–83].
Therefore, the incidence of osteogenic tumors in Pol b Tg mice is
considerably higher than incidences cited in the literature. While the
vertebral column including caudal vertebrae (tail) has previously
been noted as a common site of osteogenic tumors in mice [81], most
reports do not detail the specific sites of osteogenic bone tumors.
Glomerulonephritis and related renal lesions are common
findings in C57BL/6 mice [60]. However, it is not clear whether
the incidence of glomerulonephritis in the Pol b model is higher
that that in C57BL/6 mice due to lack of available data in two-
year old C57BL/6 mice.
A higher level of Pol b expression has been found in human
intestinal adenocarcinoma than in other organs tumors [3,84]. In this
study, we observed a variable outcome in that ESC and EA presented
with decreased expression of Pol b whereas SA and TFC showed
elevated Pol b expression. In all cases, the efficiency of the DNA
repair system (Pol b) might be compromised due to altered PTM or
complex formation [84]. Unfortunately, there have been no reports
about the relationship between Pol b expression and osteogenic
tumors in humans and animals. Bergoglio and colleagues reported
that tumor induction could not be seen in a Pol b Tg mouse model
with thymus-specific Pol b transgene expression, suggesting that Pol b
over-expression is not sufficient to initiate tumorigenesis in vivo [59]. In
our Pol b Tg mice, over-expression of Pol b in most systemic tissues
was confirmed and the degree of over-expression of Pol b in small
intestine was shown to be similar to that in lens [46]. Therefore, we
believe that the relationship between lesion pathogenesis and over-
expression of Pol b might reflect organ specificity.
The relationship between Pol b over-expression and human
carcinogenesis remains to be elucidated. Previous reviews have
Figure 3. Osteogenic tumors of tails in Pol b Tg mice (H & E stain). (A) Osteoma (arrow) in the central area of tail (magnification620,
Decalcified). (B) Higher magnification of panel A. Irregular trabecular formation by spindle tumor cells (magnification6200). (C) Osteosarcoma. The
tumor occupied almost the entire subcutaneous area of the tail (magnification620). (D) Spindle tumor cells resemble fibroblastic mesenchymal cells
and proliferated with production of a small amount of osteoid deposition (magnification6400).
doi:10.1371/journal.pone.0006493.g003
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reported that greater than 30% of human tumors have elevated
expression of Pol b [1] or express dysfunctional Pol b proteins [2].
Additional research is needed to analyze the relationship between
Pol b over-expression and intestinal carcinogenesis and the
understanding of the potential extrapolations from our model to
humans due to over-expression of Pol b. This mouse model might
be a useful tool for cancer chemotherapy as well as evaluating the
environmental and genetic factors that cooperate with Pol b
expression variation to impact hyperplasia and tumor formation.
Materials and Methods
Animals
DNA polymerase Pol b transgenic mice were described
previously [46]. Genotyping was as described [46]. These mice
(fifteen male and twenty-one female), express Flag-tagged Pol b
(TetOp-Flag_polb-tTA) and were developed in B6SJL-hybrid
females and then back-crossed onto C57BL/6 mice [46]. The Pol
b expression pattern and the level of over-expression was described
previously [46]. These mice over-express Pol b in almost all
organs, including stomach and small intestine [46]. This mouse
strain is available from the NIH-sponsored Mutant Mouse
Regional Resource Centers (MMRRC) (Strain name: B6.Cg-
Tg(TetOp-Polb/tTA)2Sbl/Mmmh, Stock number: 000356-MU).
Details for this strain are available at http://www.mmrrc.org/
strains/356/0356.html. All breeding was at NIH using IACUC
and ALAAS approved protocols for the duration of the study. The
transgenic mice used in the study were crossed to C57BL/6
(Taconic) for .5 generations, as in the previous study [46]. Each
Tg animal is considered a heterozygous Tg mouse in that breeding
was only performed using either a transgenic male and C57BL/6
female or a C57BL/6 male and transgenic female. Transgenic
mice were never inter-bred. Mice were housed in solid-bottom
polycarbonate cages. Filtered room air underwent at least 10
changes per hour. The animal room was maintained at 22 +/2
2uC with 50 +/2 15% relative humidity and a 12-hour light-dark
cycle. Irradiated NTP-2000 pelleted feed (Zeigler Bros., Inc.,
Gardner, PA) and water were available ad libitum. Animal handling
and husbandry were conducted in accordance with NIH
guidelines [85].
Figure 4. Representative photomicrographs (H & E stain) of lenticular and glomerular damages in Pol b Tg mice. (A) Mature cataract
characterized by degeneration/necrosis (liquefaction) and vacuolar formation in lens fibers (magnification620). (B) High-magnification of figure a.
Irregular proliferation of spindle lens fiber cells without production of normal lens fibers; necrosis and calcification are present (magnification6400).
(C) Glomerular hyalinization with basement membrane thickening of Bowman’s capsule, basophilic tubules, and tubular vacuolation in the renal
cortex (magnification6400). (D) Glomerular hypercellularity with basement membrane thickening (magnification6400).
doi:10.1371/journal.pone.0006493.g004
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Pathology
Necropsies were performed on all mice after euthanization at
the age of 24 months. Euthanasia was by asphyxiation with carbon
dioxide and mice were necropsied within 5 min of death. At
necropsy, all tissues including masses and macroscopical abnor-
malities were removed and fixed in 10% neutral buffered formalin.
After fixation, the following tissues were trimmed, dehydrated,
cleared, and paraffin-embedded: liver, gallbladder, lung, thyroid
gland, parathyroid gland, salivary gland, spleen, heart, kidney,
stomach, duodenum, jejunum, ileum, cecum, colon, pancreas,
mesenteric lymph node, skin, mammary gland, brain, eye, urinary
bladder, testis, epididymis, prostate, seminal vesicle, ovary, uterus,
vagina, adrenal gland, and pituitary gland. Other lymph nodes
(mediastinal, pancreatic, cervical, and/or perirenal) were exam-
ined when macroscopical lesions were detected. In addition, for
animals that had macroscopical tail lesions, samples were
decalcified prior to routine processing. Five-micron thick sections
were mounted onto glass slides, stained with hematoxylin and
eosin (H&E), and examined microscopically. The severity of non-
neoplastic lesions was graded on a four-point scale of 1 =minimal,
2 =mild, 3 =moderate, and 4=marked. Histopathology evalua-
tion was performed by two pathologists (KY and AN). Previously
published histopathological terminology and diagnostic criteria
were used [50,60,63,64].
Laser-Capture Microdisection of Paraffin-Embedded
tissue and tumor samples
RNA was isolated from laser capture micro-dissected Formalin-
Fixed Paraffin-Embedded (FFPE) tissue and tumor samples using
the CellcutTM instrument (Molecular Machines and Industries,
Haslett, MI). Two sections (8 mm) were placed on five polyeth-
ylene terephthalate (PET) foil slides. A detailed protocol for
staining and the LM process is available on the NIEHS Laser
Microdissection Core Facility web site [86,87]. Using the Pure-
LinkTM FFPE RNA Isolation Kit (Invitrogen Life Technologies,
Carlsbad, CA.), the LM samples and whole section controls were
lysed and RNA isolated on the same day.
Quantitative RT-PCR Analysis
Expression of mouse and human Pol bmRNA was measured by
quantitative RT-PCR using an Applied Biosystems StepOnePlus
system. Briefly, 80,000 MEF cells (WT, WT expressing the Flag-
Pol b transgene and Pol b KO) were lysed and reverse transcribed
using the Applied Biosystems TaqmanH Gene Expression Cells-to-
CTTM Kit. Each sample was analyzed in triplicate and the results
shown are an average of all three analyses. Analysis of mRNA
expression was conducted as per the manufacturer (DDCT
method) using Applied Biosystems TaqManH Gene Expression
Assays (human POL b: part #4331182, Hs01099715_m1; mouse
Pol b: part #4331182, Mm00448234_m1) and normalized to the
expression of mouse b-actin (part #4352933E).
For the analysis of the Tg mouse tissue, RNA was extracted as
described above and cDNA was synthesized from 30 ng of RNA
using the Applied Biosystems High Capacity cDNA Reverse
Transcription Kit (part #4375575). The cDNA was pre-amplified
for 10 cycles using the TaqManH PreAmp Master Mix (part #
4391128) and diluted 1:5. The pre-amplified cDNA was next
analyzed using the Applied Biosystems TaqManH Gene Expres-
sion Assays (human POL b: part #4331182, Hs01099715_m1;
mouse Pol b: part #4331182, Mm00448234_m1) and normalized
to the expression of mouse b-actin. Expression analysis was
determined using the DDCT protocol as per the manufacturer to
determine the relative quantitation of Flag-Pol b expression, as
compared to the mouse b-actin among all samples. From the tissue
samples, expression was normalized to the level of expression in
the brain of Tg mice.
Immunohistochemistry for Pol b in human epithelial
tumors
Tissues samples [Esophageal Squamous Carcinoma (ESC),
Esophageal Adenocarcinoma (EA), Thyroid Follicular Carcinoma
(TFC) and Stomach Adenocarcinoma (SA) and surrounding
normal tissue] were obtained through the Tissue and Research
pathology Services (TARPS), University of Pittsburgh Cancer
Institute. Five cases were examined for each of the types of
Figure 5. Decreased expression of Pol b in human esophageal
adenocarcinoma. (A) Photomicrograph of sections of esophageal
adenocarcinoma and esophageal squamous mucosa stained for Pol b
expression by immunohistochemistry. Top images reflect magnifica-
tion640 and the inserts depict magnification6100. (B) Bar graph
representing relative expression level of Pol b in various tumors
(stippled, open bars) and pathologically normal (grey bars) epithelial
tissues. Immunoreactivity Score is the average of 5 different tumor
samples each evaluated in two independent analyses.
doi:10.1371/journal.pone.0006493.g005
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carcinoma. Five-micron thick sections of paraffin-embedded tissue
on glass slides were either stained with hematoxylin and eosin
(H&E) or analyzed for Pol b expression by immunohistochemistry.
Labeling was performed on formalin-fixed, paraffin-embedded
tissues by incubation with antibodies against Pol b (Abcam,
polyclonal, cat#AB53059, diluted 1 in 5000). To ensure even
staining and reproducible results, sections were incubated by slow
rocking overnight in primary antibody (4uC) using the Antibody
AmplifierTM(ProHisto, LLC, Columbia, SC). Following incuba-
tion with primary antibody, sections were processed with a rabbit
polyclonal EnVision+System-HRP kit (DakoCytomation, Carpin-
teria, CA) according to the kit protocols. The chromogen was
diaminobenzidene and sections were counter stained with 1%
methyl green. The negative controls were tissues from Pol b
knockout mice, which were negative for staining. Immunohisto-
chemistry was quantified by two independent investigators in a
blind fashion as previously described [88]. Cases with a
disagreement of both investigators on the immunoreactive score
were discussed using a multiheaded microscope until consensus
was achieved. A score was calculated based of the percentage of
positive tumor cells (,10%=1; 11–50%=2; 51–80%=3;
.80%=4) multiplied by the staining intensity (negative = 0;
weak= 1; moderate = 2; strong = 3). For the immunoreactive score
(IRS) the scores for the percentage of positive cells and the staining
intensity were multiplied, resulting in a value between 0 and 12.
For immunohistochemical quantification, mean differences be-
tween groups were compared by one-way analysis of variance with
Scheffe multiple comparison tests. The P-value chosen for
significance in this study was 0.05.
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